Eyevance launches Zerviate in US
Eyevance Pharmaceuticals has launched Zerviate, a treatment for ocular itching related to allergic conjunctivitis, in the United States, according to a press release.
Zerviate (cetirizine ophthalmic solution 0.24%) is formulated with the vehicle Hydrella, which contains glycerin and hydroxypropyl methylcellulose. These are common in tear lubricants and help to comfortably deliver the cetirizine molecule, the release said.
“Eyevance is building its core business around the commercialization of standout anterior segment and ocular surface products,” Jerry St. Peter, CEO, director and co-founder of Eyevance, said in the release. “Accordingly, Zerviate’s launch represents a critical milestone as we continue to enhance our product offerings to serve all treatable conditions within our core therapeutic areas.”
Eyevance has an exclusive licensing agreement with Nicox and is responsible for manufacturing, regulatory and commercial activities for Zerviate in the U.S., according to a Nicox press release.